Continuous Glucose Monitoring in Non-Insulin-Treated Type 2 Diabetes.

Continuous glucose monitoring reduces glycated hemoglobin levels by 0.9 percentage points in adults with non-insulin-treated type 2 diabetes over 26 weeks.

• Why it matters: Effective management of blood glucose in non-insulin-treated type 2 diabetes is crucial to prevent complications, but the role of continuous glucose monitoring in this group has been unclear.
• What they did: A 26-week randomized trial involving 283 adults across 22 primary care practices compared CGM to routine care, measuring changes in glycated hemoglobin and glucose time-in-range.
• The result: CGM led to a significant decrease in glycated hemoglobin and increased the percentage of time glucose levels were within the target range, without severe hypoglycemia, suggesting improved glycemic control.